• 1. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 2. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 3. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 4. Alternative mixtures to R-600a. Theoretical assessment and experimental energy evaluation of binary mixtures in a commercial cooler: Mélanges alternatifs au R-600a. évaluation théorique et évaluation énergétique expérimentale de mélanges binaires dans un refroidisseur commercial.
  DanielCalleja-Anta,DanielSánchez,LauraNebot-Andres,RamónCabello,RodrigoLlopis
• 5. Alumina coating on 5 V lithium cobalt fluorophosphate cathode material for lithium secondary batteries – synthesis and electrochemical properties?
  S. Amaresh,K. Karthikeyan,K. J. Kim,Y. S. Lee RSC Adv., 2014,4, 23107-23115

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids and derivatives Pyridinecarboxylic acids

Research Briefing on 2,5-Dibromopyridine-3-carboxylic Acid (CAS: 29312-99-0): Recent Advances and Applications in Chemical Biology and Pharmaceutical Research

2,5-Dibromopyridine-3-carboxylic acid (CAS: 29312-99-0) is a halogenated pyridine derivative that has garnered significant attention in recent years due to its versatile applications in medicinal chemistry, drug discovery, and material science. This compound serves as a crucial building block for the synthesis of various pharmacologically active molecules, particularly in the development of kinase inhibitors, antiviral agents, and antimicrobial compounds. Recent studies have highlighted its potential in addressing unmet medical needs, making it a focal point in contemporary research.

One of the most notable advancements in the utilization of 2,5-dibromopyridine-3-carboxylic acid is its role in the synthesis of novel kinase inhibitors. Kinases are pivotal targets in cancer therapy, and researchers have successfully employed this compound to develop potent and selective inhibitors against specific kinase isoforms. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of derivatives of 2,5-dibromopyridine-3-carboxylic acid in inhibiting aberrant kinase activity in non-small cell lung cancer (NSCLC) cell lines, showcasing its potential as a lead compound for oncology drug development.

In addition to its applications in oncology, 2,5-dibromopyridine-3-carboxylic acid has been explored for its antiviral properties. Recent research has indicated that modifications of this compound can yield molecules with significant activity against RNA viruses, including SARS-CoV-2. A 2022 study in Bioorganic & Medicinal Chemistry Letters reported that certain derivatives exhibited inhibitory effects on viral replication by targeting essential viral enzymes, suggesting a promising avenue for the development of broad-spectrum antiviral agents.

The compound's utility extends beyond therapeutic applications. In material science, 2,5-dibromopyridine-3-carboxylic acid has been employed as a precursor for the synthesis of advanced organic frameworks and ligands for metal-organic frameworks (MOFs). These materials have shown potential in catalysis, gas storage, and sensing applications. A 2023 publication in ACS Applied Materials & Interfaces highlighted the use of this compound in creating luminescent MOFs with high selectivity for heavy metal ions, underscoring its versatility in interdisciplinary research.

Despite these promising developments, challenges remain in optimizing the synthetic routes and improving the bioavailability of derivatives derived from 2,5-dibromopyridine-3-carboxylic acid. Recent efforts have focused on green chemistry approaches to reduce the environmental impact of its synthesis, as well as structural modifications to enhance its pharmacokinetic properties. Collaborative research between academia and industry is expected to drive further innovations in this area.

In conclusion, 2,5-dibromopyridine-3-carboxylic acid (CAS: 29312-99-0) continues to be a molecule of significant interest in chemical biology and pharmaceutical research. Its diverse applications, from drug discovery to material science, highlight its importance as a multifunctional building block. Ongoing studies are likely to uncover new therapeutic and industrial uses, solidifying its role in advancing scientific and technological progress.

• 55304-85-3(2,6-dibromopyridine-3-carboxylic acid)
• 6311-35-9(6-bromopyridine-3-carboxylic acid)
• 942473-59-8(2,5-dibromopyridine-4-carboxylic acid)
• 73027-77-7(4,6-Dibromonicotinic acid)
• 35905-85-2(2-bromopyridine-3-carboxylic acid)
• 52718-95-3(methyl 2-bromopyridine-3-carboxylate)
• 29241-64-3(5,6-Dibromonicotinic acid)
• 1214375-74-2(Ethyl 2,5-dibromonicotinate)
• 852181-11-4(2,5-Dibromonicotinaldehyde)
• 1020056-98-7(2,3-Dibromoisonicotinic Acid)